Cancer
Conditions
Brief summary
FRACTal study is the first exploration of detection of FSHR as a blood biomarker for the diagnosis of cancer. A first cohort will explore several common (e.g. breast, prostate) or rare (e.g. uveal melanoma) cancers, that are frequently treated at Institut Curie. This first cohort will include n=10 patients per histological type except for breast cancer (n=50). 100 patients are expected in this cohort. A second cohort will explore the more promising histological type (if any) in term of incidence of detection. 100 patients are expected for this second cohort.
Interventions
PROCEDUREblood sample for FSHR analysis
Sponsors
Institut Curie
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient diagnosed with localized cancer and corresponding to the different types explored. The cancer can be already diagnosed or not (strong suspicion) 2. Age\> 18 3. Written informed consent
Exclusion criteria
1. Previous treatment for the tumoral disease 2. Personal history of cancer diagnosis in the last 10 years 3. Pregnant and/or breastfeeding women 4. Person deprived of liberty or under guardianship (including curatorship) 5. psychiatric illness/social situation that would interfere with the protocol or limit compliance with study requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sensitivity of blood FSH R detection in cancer patients | end of the study, up to two years |
Secondary
| Measure | Time frame |
|---|---|
| variability of blood FSH-R in the same tumoral type and between different tumoral types | end of the study, up to two years |
| comparison of blood FSH-R with blood from healthy donor | end of the study, up to two years |
Countries
France
Outcome results
None listed